Evidence question

PubMed sourcedAbstract-based analysisUpdated Sep 2026Human reviewedUpdated Aug 2026

Evidence / Menopause & Women's Health

CoverageMenopause & Women's Health

Is menopause associated with cognitive changes or brain fog?

Reviewed by Neal Rouzier, MD, Preventive Medicine · Aug 2026

Updated Aug 2026·10 studies analyzed·2 core studies·Applies to: perimenopausal and early postmenopausal women

Bottom line

Many women report subjective cognitive difficulty during perimenopause, often linked to sleep disruption and vasomotor symptoms. Objective cognitive testing shows subtle changes in some cohorts, but HRT is not established as a treatment for brain fog alone.[1–6]

Evidence confidence

Evidence Confidence

Limited
LimitedModerateHigh

The available studies are limited in design quality, directness, or consistency, so scientific certainty remains limited.

Key uncertainty. Mechanisms and reversible components remain active research areas.

Ask RAGMD

Get the live evidence synthesis

10 complimentary queries. Full clinical intelligence — PubMed citations, conflict analysis, Evidence Confidence — with 7-day free trial.

Ask this questionStart free trialWhy physicians use RAGMD

Also asked

Menopause cognitive symptoms▼

Many women report subjective cognitive difficulty during perimenopause, often linked to sleep disruption and vasomotor symptoms. Objective cognitive testing shows subtle changes in some cohorts, but HRT is not established as a treatment for brain fog alone.

Perimenopause memory estrogen▼

Many women report subjective cognitive difficulty during perimenopause, often linked to sleep disruption and vasomotor symptoms. Objective cognitive testing shows subtle changes in some cohorts, but HRT is not established as a treatment for brain fog alone.

Body of evidence

Clinical Evidence Brief

RAGMD analyzed 10 relevant studies.

Overall finding

8 studies address vasomotor symptom associations, with weighted findings showing mixed findings. 2 studies address subjective cognitive complaints, with weighted findings showing a negative association. 2 studies address long-term cognitive decline / dementia, with weighted findings showing a negative association. 2 studies address venous thromboembolism, with weighted findings showing a positive association. 4 randomized or systematic-review reports and 5 observational studies address treatment.

Evidence by outcome

Direction: ↑ Favors treatment / reassuring · ↓ Harm signal · ↔ No clear effect · ± Mixed · ↗ Observational link · ? Unclear

Mixed

Vasomotor symptom associations

moderate · 8 studies

8 studies address vasomotor symptom associations, with weighted findings showing mixed findings. This is a patient-reported / subjective outcome.

Patient-reported

Studies

PMID 41307293PMID 29322164PMID 26838086PMID 38016166PMID 36749328PMID 40253593PMID 42606770PMID 34513605
Negative link

Subjective cognitive complaints

moderate · 2 studies

2 studies address subjective cognitive complaints, with weighted findings showing a negative association. This is a patient-reported / subjective outcome.

Patient-reported

Studies

PMID 38888619PMID 34513605
Negative link

Long-term cognitive decline / dementia

moderate · 2 studies

2 studies address long-term cognitive decline / dementia, with weighted findings showing a negative association. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 41307293PMID 34513605
Positive link

Venous thromboembolism

moderate · 2 studies

2 studies address venous thromboembolism, with weighted findings showing a positive association. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 41307293PMID 36749328
Positive link

Breast cancer

moderate · 2 studies

2 studies address breast cancer, with weighted findings showing a positive association. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 41307293PMID 36749328
Unclear

Blood pressure

moderate · 1 study

1 study addresses blood pressure, with weighted findings showing unclear findings. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 38888619

Magnitude / clinical importance

Validated effect estimates in the analyzed set include RR 1.17; or 4. Statistical significance is not the same as clinical importance.

Where quantified, effects were often statistically detectable but small in absolute terms.

Agreement across studies

Most studies agree on vasomotor symptom associations (mixed findings), while long-term cognitive decline / dementia findings are a negative association and more consistent across domains.

Supports main conclusion: 5 · Neutral / mixed: 5 · Credible conflicting: 0

Study counts describe the landscape; RAGMD weights studies according to design, quality, and directness.

Conflicting findings

  • Long-term follow-up of women using hormone therapy suggests that the risk profiles vary between combined hormone therapy and oestrogen-only therapy.
  • MHT has a complex pattern.
  • Brain fog, referring to menopause-related subjective cognitive difficulties, is common in midlife women.

Risks & harms

1 study reports safety-relevant findings. Design mix: Narrative review. Rare-event inference should not rest on underpowered trials alone.

Who this applies to

Most studies included perimenopausal and early postmenopausal women.

What remains uncertain

  • Mechanisms and reversible components remain active research areas.
  • Mechanisms and reversible components remain active research areas.
  • Typical subjective cognitive complaints are not established as equivalent to dementia.

Clinical takeaway

Evaluate sleep, mood, thyroid status, and vasomotor burden before attributing cognitive complaints to menopause alone. Hormone therapy is not established treatment for subjective brain fog without other indications for estrogen.

Mixed

Vasomotor symptom associations?

Mixed findings

moderate[41307293 · 29322164 · 26838086 · 38016166 · 36749328 · 40253593 · 42606770 · 34513605]

Negative link

Subjective cognitive complaints?

A negative association

moderate[38888619 · 34513605]

Negative link

Long-term cognitive decline / dementia?

A negative association

moderate[41307293 · 34513605]

Positive link

Venous thromboembolism?

A positive association

moderate[41307293 · 36749328]

Positive link

Breast cancer?

A positive association

moderate[41307293 · 36749328]

Unclear

Blood pressure?

Unclear findings

moderate[38888619]

Unclear

Mortality?

Unclear findings

moderate[41307293]

Unclear

Fertility / spermatogenesis?

Unclear findings

moderate[41307293]

4 randomized or systematic-review reports and 5 observational studies address treatment. Weighted treatment findings show mixed findings.

4 RCT / systematic review · 5 observational

Large randomized trials strongly influence the conclusion

2 landmark studies with randomized or systematic-review designs strongly inform this conclusion.

Supporting studies provide additional context

8 supporting studies add context beyond the core evidence base.

Regimen & duration

Differences in hormone type, dose, duration, and patient population affect how results should be interpreted.

Long-term uncertainty

Study quality or consistency across available evidence limits certainty.

10 analyzed studies

Strongest evidence

Current psychiatry reports2023

Landmark studyPMID 37755656

Cognitive Problems in Perimenopause: A Review of Recent Evidence.

PURPOSE OF REVIEW: To review recent research regarding cognitive problems during perimenopause, including which menopause-related symptoms, demographic variables, stress exposures, and neural biomarkers are associated with cognitive problems and which interventions demonstrate efficacy at improving cognitive performance. RECENT FINDINGS: Cognitive problems are common during perimenopause and have a significant impact on a substantial proportion of women.

Review
Evidence
Relevance
Menopause (New York, N.Y.)2024

Landmark studyPMID 38888619

Menopause and brain fog: how to counsel and treat midlife women.

Brain fog, referring to menopause-related subjective cognitive difficulties, is common in midlife women. Longitudinal studies find small but reliable declines in objective memory performance as women transition into perimenopause, and these are not explained by advancing age alone.

Study
Evidence
Relevance

Supporting literature

Long-term hormone therapy for perimenopausal and postmenopausal women.

Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial.

Hormone Therapy for Relieving Postmenopausal Vasomotor Symptoms: A Systematic Review.

+5 more

More in this focus area

Related evidence analyses

Other structured clinical questions in Menopause & Women's Health.

Does hormone replacement therapy increase breast cancer risk?

Combined estrogen-progestin therapy is associated with a small increased breast cancer risk in WHI and observational data. Estrogen-alone in hysterectomized women showed lower risk in WHI, but interpretation depends on regimen, duration, and individual risk factors.

10 linked studies

Does hormone replacement therapy reduce cardiovascular risk in early menopause?

The timing hypothesis suggests earlier initiation may differ from late initiation, where WHI showed harm for combined therapy. Current guidelines emphasize individualized risk assessment rather than routine cardioprotection.

14 linked studies

Does hormone replacement therapy increase venous thromboembolism risk?

Oral estrogen increases venous thromboembolism risk compared with no therapy. Transdermal estrogen appears to carry lower thrombotic risk in observational studies and is often preferred in women at elevated VTE risk.

14 linked studies

Is there a critical timing window for cardiovascular benefit from HRT?

The critical-window concept proposes that starting HRT closer to menopause may yield different cardiovascular effects than starting later. WHI subgroup analyses inform but do not prove this hypothesis for routine practice.

14 linked studies

Go deeper on Menopause & Women's Health

Full evidence synthesis, study comparisons, conflicting evidence, and expert commentary are available with RAGMD. Ask follow-up questions, explore related topics, and see how the evidence has evolved.

Ask RAGMDExplore Menopause & Women's HealthView pricing